Key regulatory concept: AMT designation is for the manufacturing method, and it can be held in (or supported by) a DMF

FDA’s Advanced Manufacturing Technologies (AMT) Designation Program is intended for a method (or combination of methods) of manufacturing a drug that incorporates novel technology (or an established technology used in a novel way) and is mature enough to consistently and reliably manufacture product in the specific context of use for which designation is sought ¹¹⁹³⁰⁷.

Importantly for your model (linker provider + internal ADC + multiple licensees): FDA’s AMT guidance explicitly contemplates that a designated AMT holder can be a DMF holder and can authorize NDA/ANDA/BLA/IND applicants to incorporate by reference information about the designated AMT (e.g., via a DMF and authorization) ¹²²²³. Multiple applications may reference the same designated AMT, but each application is assessed on its own merits and must explain how the AMT is used and why that use matches the designated context of use ²²¹⁶.

Practical pathway to request AMT designation (what to do and how to submit)

Where/how to submit

• Submit the AMT designation request electronically by email to [email protected] with the subject line REQUEST FOR AMT DESIGNATION (uppercase) ²³.
• If the request includes confidential commercial information, use FDA’s secure messaging partners and mark confidential/trade secret information per 21 CFR 20.61(d); contact [email protected] to be added to secure messaging partners ²³.

When to submit (timing and maturity)

• AMT designation requests are made independently of application submissions; there is no single required development stage, but you should submit once you have sufficient data and information to demonstrate eligibility ¹⁹²³.
• If the technology is not yet mature enough to reliably manufacture in the intended context of use, FDA recommends early engagement with CDER’s Emerging Technology Team (ETT) or CBER’s Advanced Technologies Team (CATT) instead of (or before) an AMT designation request ¹⁹.

What FDA expects in the AMT designation request (content)

At minimum, include:

• Requestor contact information (name, address, U.S. main point-of-contact, email, phone) and whether the request is for CDER, CBER, or both ²³.
• A clear description of the AMT and the context of use (which manufacturing step(s), scale, and how it will be used) and why that use is consistent with the designation request ¹²².
• Supporting technical data showing the method is mature and can consistently and reliably produce material in the claimed context of use; FDA will deny incomplete requests or those that do not meet statutory criteria ¹¹⁹²⁰.
• If you are not an applicant and lack drug-specific data, FDA allows use of model drug data to demonstrate parameters/limitations/context of use ²³.
• A quality/supply rationale: FDA prioritizes AMTs that significantly improve product quality, address known quality issues, or increase/maintain supply of critical drugs ¹²¹.

FDA process expectations after submission

• FDA intends to acknowledge receipt, confirm completeness, and evaluate; statutory requirement to complete designation determinations within 180 calendar days of receipt ²³²⁰.
• FDA assigns a designated lead to facilitate communications and coordinate discussions as needed ²³¹⁹.

How to frame an ADC linker manufacturing approach as an “AMT” (what to claim and what evidence to show)

FDA’s AMT framing is broad and includes concepts such as continuous manufacturing, advanced process control/PAT, real-time release testing, advanced analytics, and digital/automation elements ^11921307. For an ADC linker (or drug-linker intermediate), the strongest AMT narratives typically connect the technology to better control of linker CQAs and/or more reliable supply.

Examples of AMT “hooks” that map well to linker manufacture/control

• Continuous/flow chemistry for key synthetic steps or telescoped operations, supported by process characterization and run data showing consistent control of linker CQAs ¹¹⁹²⁰.
• PAT / advanced process control to monitor and control critical process parameters tied to linker CQAs (e.g., purity, residual solvents, reactive impurity levels, functional group integrity), potentially enabling real-time assurance of CQAs ¹¹⁹²¹.
• Advanced analytics / multivariate models to detect/predict variability affecting linker CQAs and demonstrate improved consistency and reduced risk ¹¹⁹²¹.
• Automation/digital control (validated control systems, electronic batch records, audit trails) that demonstrably reduces variability and strengthens lifecycle control ¹¹⁹²¹.

Evidence FDA will expect you to provide (practically)

Across the AMT guidance and ADC precedents, FDA expects enough data to show:

• The method is novel in the context of use and not merely “standard practice” ¹²²³⁰⁷.
• The method is mature and can reliably produce material meeting specifications in the intended context of use ¹¹⁹²⁰.
• The method provides a material quality or supply benefit ¹²¹.
• The control strategy is credible: link CPPs → CQAs, show process characterization, and provide batch/continuous run data demonstrating consistent performance ¹¹⁹²⁰.

DMF strategy for an ADC linker used internally and licensed to multiple clients

Can an ADC linker/intermediate be in a DMF?

Yes. FDA’s AMT guidance explicitly states a designated AMT holder can be a DMF holder and can authorize applicants to incorporate by reference information about the designated AMT ²²¹⁵²³.

ADC precedents show FDA has accepted DMF cross-references for drug-linker intermediates (e.g., vcMMAE) and relied on DMF content for stability, impurity/residual controls, and manufacturing information ^18415857. For example, in one BLA review FDA noted the applicant referenced all CMC information on the linker-drug intermediate to a DMF and the DMF was reviewed and found adequate ¹⁸⁴¹.

DMF type selection (what the sources support)

• FDA’s Drug Master Files: Guidelines describes Type II DMFs as covering drug substance, drug substance intermediate, and material used in their preparation ¹³³, and indicates a Type II DMF should summarize significant manufacturing steps and controls for a drug intermediate or substance ¹⁴¹³.
• The AMT guidance itself does not prescribe a DMF type and points to 21 CFR 314.420 and the draft DMF guidance for DMF details ²².

Practically, for an ADC linker that is a drug substance intermediate or a controlled intermediate used in conjugation, a Type II DMF is the most directly supported category in the cited DMF guidance ^1331413. (If the linker is positioned as an excipient-like proprietary material, Type IV is described for excipients/materials used in their preparation ¹³³, but ADC linker intermediates in the cited ADC BLAs were handled as drug substance intermediates referenced to DMFs ^18415758.)

What CMC content FDA expects in a linker/intermediate DMF (based on ADC precedents)

ADC BLA reviews that relied on linker/intermediate DMFs show FDA expects the DMF to be complete and reviewable, including:

• Identity/structure and general properties for the intermediate ¹⁵³⁵.
• Full manufacturing information: manufacturer(s), detailed process description, process controls, control of raw materials, control of critical steps and intermediates, and process development history/versions ^11331535.
• Impurity/residual controls relevant to conjugation: limits and supporting data for conjugatable impurities, residual solvents, and residual metals (e.g., palladium) were provided in a linker-intermediate DMF and found acceptable ¹⁸²².
• Stability/hold-time data for the intermediate (FDA accepted DMF-provided hold-time/stability control data) ¹⁸²²⁵⁸.
• Analytical procedures and validation, batch analyses, reference standards/materials, and specifications with justification ^11331535.

These expectations are consistent with general DMF principles that DMFs provide confidential detailed information about facilities/processes/articles used in manufacturing and are reviewed when referenced by an application ¹³⁴¹³⁵.

Multi-client referencing mechanics: LOAs, cross-references, and avoiding “authority not granted”

Letters of Authorization (LOAs): what to include and how to operationalize

FDA’s DMF guidance is explicit that before FDA will review DMF information in support of an application, the DMF holder must submit a Letter of Authorization (in duplicate) permitting FDA to reference the DMF ¹³⁷. The LOA should include:

• Date
• DMF holder name
• DMF number
• Name(s) of person(s) authorized to incorporate the DMF by reference
• Specific product(s) covered
• Submission date(s) of the DMF material being authorized ¹³⁷.

Operationally, ADC and non-ADC review records show FDA tracks whether authority was granted; action-code tables include a distinct outcome for “Authority to reference not granted” ¹⁷⁷¹⁷⁶. This is a common avoidable failure mode—so issue client-specific LOAs and ensure each applicant includes the LOA in their submission.

How each applicant should reference the linker DMF

Across multiple reviews, best practice is:

• Applicant lists the DMF number in their submission (often in Module 1 / related-supporting documents and/or Form 356h) so FDA can locate it ¹⁴⁴.
• Applicant includes a concise bridging statement describing how the DMF material is used in their product and what product-specific controls they provide (e.g., downstream conjugation controls, DP controls) ^1218412185.
• FDA will review the DMF as part of the application and must find it adequate to support that application ^18411833.

Change control and notifications when multiple clients rely on the same DMF/AMT

AMT-designated holders have explicit lifecycle obligations:

• Proposed changes should be emailed with subject PROPOSED CHANGE FOR DESIGNATED AMT, identify center (CDER/CBER/both), describe the change, include supporting data, and list persons/entities granted a right of reference ²⁰¹¹⁰.
• Agreements/LOAs should include communication mechanisms for future changes, and the AMT holder should provide a list of right-of-reference entities when notifying FDA of changes ²⁰¹¹⁰.
• FDA will assess whether changes affect continued eligibility/context-of-use alignment; the AMT holder must inform applicants about changes, including changes to context of use ²⁰¹¹⁰.

Separately, DMF guidance requires DMF holders to submit annual reports and warns failure to update can delay dependent actions or lead to DMF closure ¹³⁸. DMF holders must also submit changes/additions (including changes in authorization for customers) and cross-reference prior submissions ¹³⁸.

Special considerations when the linker is used in the provider’s own ADC and licensed to clients

Division of responsibilities (what FDA expects)

FDA’s AMT guidance is clear that even with AMT designation, each applicant remains responsible for demonstrating in their application CMC that the designated AMT is suitable for inclusion; FDA may leverage knowledge from designation but still requires required technical data in the application CMC ²⁴¹¹².

For a shared linker DMF model:

• DMF/AMT holder: maintains the DMF and AMT lifecycle communications, provides LOAs, submits amendments/annual reports, and notifies LOA holders of changes ^{13813513720110}.
• Each NDA/IND/BLA applicant: includes LOA and cross-reference, and provides product-specific CMC (e.g., conjugation process, DP controls, potency/functional assays, container/closure, DP stability) ¹⁵⁸⁵⁵.

BLA-specific caution (important for ADCs regulated as biologics)

The AMT guidance includes a specific expectation for BLAs: even if a BLA applicant is authorized to rely on a designated AMT, FDA expects supporting data/information for drug substance, drug substance intermediate, and drug product to be submitted directly in the BLA rather than only incorporated by reference ²²¹⁶. This reflects the expectation that a BLA holder has knowledge of and control over manufacturing for the licensed biological product ¹²².

Practically, this means your DMF can still be valuable, but for BLA clients you should plan for:

• More direct CMC content in the BLA (or at least robust sponsor-accessible data packages), and
• Early alignment with each BLA sponsor on what must be included directly vs referenced.

Harmonization risk when DMF and applications overlap

ADC precedents show FDA may require harmonization between DMF and application CMC:

• FDA recommended harmonizing CMC information contained in the DMF and the BLA within three months post-approval in one ADC case ²⁷⁰²⁶⁵.
• FDA may review overlapping content in the application rather than the DMF and use the DMF only for DMF-only content ²⁶⁷.

For a multi-client linker DMF, this implies you should:

• Keep a single “source of truth” for linker CMC in the DMF, and
• Provide controlled, consistent summaries to each client for inclusion in their submissions to avoid divergence.

Recommended execution plan (stepwise)

1) Define the AMT “context of use” for the linker

Document exactly what step(s) are AMT-enabled (e.g., continuous flow synthesis of a key intermediate, PAT-enabled purification endpoint control, RTRT strategy) and what material the DMF covers (linker, activated linker, drug-linker intermediate).

2) Build the AMT designation data package around maturity + benefit

Prepare data showing:

• Reproducibility and control (batch/continuous run data, process characterization) ¹¹⁹²⁰
• Novelty in context of use ¹²²³⁰⁷
• Quality/supply benefit ¹²¹

3) File/maintain a Type II DMF for the linker/intermediate and make it “review-ready”

Include the CMC elements FDA has actually relied on for linker intermediates:

• Identity/structure, manufacturing process/controls, impurity/residual controls (solvents/metals/conjugatable impurities), stability/hold-times, analytical methods/validation, batch analyses ^1535182258.
  Maintain annual reports and amendments ¹³⁸.

4) Operationalize multi-client access

• Issue client-specific LOAs meeting FDA LOA content expectations ¹³⁷.
• Provide each client a “how to reference this DMF” instruction set (DMF number, sections relied upon, and what the client must still include in their IND/NDA/BLA).
• Implement a formal change-notification mechanism consistent with AMT change expectations (include list of right-of-reference entities in FDA change emails) ²⁰¹¹⁰.

5) Submit the AMT designation request

Email the request to [email protected] with the required subject line and include center designation and U.S. contact details ²³. Use secure messaging for confidential information ²³.

6) Align with each client’s application type (IND/NDA vs BLA)

• For IND/NDA clients: DMF cross-reference can carry substantial linker CMC, but each applicant still must justify suitability in their CMC ²⁴¹¹².
• For BLA clients: plan for more direct DS/DSI/DP supporting data in the BLA ²²¹⁶.

What “good” looks like for FDA review (practical success criteria)

• FDA can review the linker/intermediate DMF and find it adequate to support each referencing application (as seen for vcMMAE DMFs supporting BLAs) ¹⁸⁴¹⁵⁸.
• LOAs are in place early enough that FDA does not code the DMF as “authority not granted” (a known failure mode in action-code systems) ¹⁷⁷¹⁷⁶.
• The AMT request clearly defines context of use, shows maturity, and provides supporting data demonstrating consistent, reliable manufacture and a quality/supply benefit ^119202122.
• Change control is credible: FDA and all LOA holders can be notified of proposed changes with supporting data and a current list of right-of-reference entities ²⁰¹¹⁰.

If you want, I can draft (a) an AMT designation request outline tailored to a linker (with a suggested “context of use” statement), and (b) an LOA template that satisfies the required LOA elements and also embeds the AMT change-notification expectations for multi-client use ^1372011023.